Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the US Market
15 October 2018 - - Indian drugmaker Dr. Reddy's Laboratories Ltd (BSE: 500124), (NSE: DRREDDY), (NYSE: RDY) has received approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the US Food and Drug Administration (USFDA), the company said.

The company is working towards launching the product.

The Aggrenox brand and generic had US sales of approximately USD 183m MAT for the most recent twelve months ending in August 2018 according to IMS Health.

Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.

Aggrenox is a registered trademark of Boehringer Ingelheim.

Dr. Reddy's Laboratories is an integrated pharmaceutical company.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.